** Shares of drugmaker Aurinia Pharmaceuticals AUPH.O rise 4% to $9 premarket
** Co says its autoimmune drug, aritinercept, significantly reduced antibody levels in the blood of healthy participants, in an early-stage trial
** Aritinercept cut antibody levels by up to 55% for IgM, 48% for IgA, and 20% for IgG after 28 days, with effects lasting long enough to support once-monthly dosing - AUPH
** The trial tested the drug at doses ranging from 5 mg to 300 mg via subcutaneous injection in 61 healthy subjects
** Aritinercept, which blocks two immune proteins, was safe at all tested doses with no serious side effects or treatment discontinuations - AUPH
** As of last close, stock down 3.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.